Cargando…

CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy

BACKGROUND: Antitumor therapeutic vaccines are generally based on antigenic epitopes presented by major histocompatibility complex (MHC-I) molecules to induce tumor-specific CD8(+) T cells. Paradoxically, continuous T cell receptor (TCR) stimulation from tumor-derived CD8(+) T-cell epitopes can driv...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Minglu, Xie, Luoyingzi, Cao, Guoshuai, Lei, Shun, Wang, Pengcheng, Wei, Zhengping, Luo, Yuan, Fang, Jingyi, Yang, Xingxing, Huang, Qizhao, Xu, Lifan, Guo, Junyi, Wen, Shuqiong, Wang, Zhiming, Wu, Qing, Tang, Jianfang, Wang, Lisha, Chen, Xiangyu, Chen, Cheng, Zhang, Yanyan, Yao, Wei, Ye, Jianqiang, He, Ran, Huang, Jun, Ye, Lilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114852/
https://www.ncbi.nlm.nih.gov/pubmed/35580929
http://dx.doi.org/10.1136/jitc-2021-004022
_version_ 1784709871372861440
author Xiao, Minglu
Xie, Luoyingzi
Cao, Guoshuai
Lei, Shun
Wang, Pengcheng
Wei, Zhengping
Luo, Yuan
Fang, Jingyi
Yang, Xingxing
Huang, Qizhao
Xu, Lifan
Guo, Junyi
Wen, Shuqiong
Wang, Zhiming
Wu, Qing
Tang, Jianfang
Wang, Lisha
Chen, Xiangyu
Chen, Cheng
Zhang, Yanyan
Yao, Wei
Ye, Jianqiang
He, Ran
Huang, Jun
Ye, Lilin
author_facet Xiao, Minglu
Xie, Luoyingzi
Cao, Guoshuai
Lei, Shun
Wang, Pengcheng
Wei, Zhengping
Luo, Yuan
Fang, Jingyi
Yang, Xingxing
Huang, Qizhao
Xu, Lifan
Guo, Junyi
Wen, Shuqiong
Wang, Zhiming
Wu, Qing
Tang, Jianfang
Wang, Lisha
Chen, Xiangyu
Chen, Cheng
Zhang, Yanyan
Yao, Wei
Ye, Jianqiang
He, Ran
Huang, Jun
Ye, Lilin
author_sort Xiao, Minglu
collection PubMed
description BACKGROUND: Antitumor therapeutic vaccines are generally based on antigenic epitopes presented by major histocompatibility complex (MHC-I) molecules to induce tumor-specific CD8(+) T cells. Paradoxically, continuous T cell receptor (TCR) stimulation from tumor-derived CD8(+) T-cell epitopes can drive the functional exhaustion of tumor-specific CD8(+) T cells. Tumor-specific type-I helper CD4(+) T (T(H)1) cells play an important role in the population maintenance and cytotoxic function of exhausted tumor-specific CD8(+) T cells in the tumor microenvironment. Nonetheless, whether the vaccination strategy targeting MHC-II-restricted CD4(+) T-cell epitopes to induce tumor-specific T(H)1 responses can confer effective antitumor immunity to restrain tumor growth is not well studied. Here, we developed a heterologous prime-boost vaccination strategy to effectively induce tumor-specific T(H)1 cells and evaluated its antitumor efficacy and its capacity to potentiate PD-1/PD-L1 immunotherapy. METHODS: Listeria monocytogenes vector and influenza A virus (PR8 strain) vector stably expressing lymphocytic choriomeningitis virus (LCMV) glycoprotein-specific I-A(b)-restricted CD4(+) T cell epitope (GP(61–80)) or ovalbumin-specific CD4(+) T cell epitope (OVA(323-339)) were constructed and evaluated their efficacy against mouse models of melanoma and colorectal adenocarcinoma expressing lymphocytic choriomeningitis virus glycoprotein and ovalbumin. The impact of CD4(+) T cell epitope-based heterologous prime-boost vaccination was detected by flow-cytometer, single-cell RNA sequencing and single-cell TCR sequencing. RESULTS: CD4(+) T cell epitope-based heterologous prime-boost vaccination efficiently suppressed both mouse melanoma and colorectal adenocarcinoma. This vaccination primarily induced tumor-specific T(H)1 response, which in turn enhanced the expansion, effector function and clonal breadth of tumor-specific CD8(+) T cells. Furthermore, this vaccination strategy synergized PD-L1 blockade mediated tumor suppression. Notably, prime-boost vaccination extended the duration of PD-L1 blockade induced antitumor effects by preventing the re-exhaustion of tumor-specific CD8(+) T cells. CONCLUSION: CD4(+) T cell epitope-based heterologous prime-boost vaccination elicited potent both tumor-specific T(H)1 and CTL response, leading to the efficient tumor control. This strategy can also potentiate PD-1/PD-L1 immune checkpoint blockade (ICB) against cancer.
format Online
Article
Text
id pubmed-9114852
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-91148522022-06-04 CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy Xiao, Minglu Xie, Luoyingzi Cao, Guoshuai Lei, Shun Wang, Pengcheng Wei, Zhengping Luo, Yuan Fang, Jingyi Yang, Xingxing Huang, Qizhao Xu, Lifan Guo, Junyi Wen, Shuqiong Wang, Zhiming Wu, Qing Tang, Jianfang Wang, Lisha Chen, Xiangyu Chen, Cheng Zhang, Yanyan Yao, Wei Ye, Jianqiang He, Ran Huang, Jun Ye, Lilin J Immunother Cancer Clinical/Translational Cancer Immunotherapy BACKGROUND: Antitumor therapeutic vaccines are generally based on antigenic epitopes presented by major histocompatibility complex (MHC-I) molecules to induce tumor-specific CD8(+) T cells. Paradoxically, continuous T cell receptor (TCR) stimulation from tumor-derived CD8(+) T-cell epitopes can drive the functional exhaustion of tumor-specific CD8(+) T cells. Tumor-specific type-I helper CD4(+) T (T(H)1) cells play an important role in the population maintenance and cytotoxic function of exhausted tumor-specific CD8(+) T cells in the tumor microenvironment. Nonetheless, whether the vaccination strategy targeting MHC-II-restricted CD4(+) T-cell epitopes to induce tumor-specific T(H)1 responses can confer effective antitumor immunity to restrain tumor growth is not well studied. Here, we developed a heterologous prime-boost vaccination strategy to effectively induce tumor-specific T(H)1 cells and evaluated its antitumor efficacy and its capacity to potentiate PD-1/PD-L1 immunotherapy. METHODS: Listeria monocytogenes vector and influenza A virus (PR8 strain) vector stably expressing lymphocytic choriomeningitis virus (LCMV) glycoprotein-specific I-A(b)-restricted CD4(+) T cell epitope (GP(61–80)) or ovalbumin-specific CD4(+) T cell epitope (OVA(323-339)) were constructed and evaluated their efficacy against mouse models of melanoma and colorectal adenocarcinoma expressing lymphocytic choriomeningitis virus glycoprotein and ovalbumin. The impact of CD4(+) T cell epitope-based heterologous prime-boost vaccination was detected by flow-cytometer, single-cell RNA sequencing and single-cell TCR sequencing. RESULTS: CD4(+) T cell epitope-based heterologous prime-boost vaccination efficiently suppressed both mouse melanoma and colorectal adenocarcinoma. This vaccination primarily induced tumor-specific T(H)1 response, which in turn enhanced the expansion, effector function and clonal breadth of tumor-specific CD8(+) T cells. Furthermore, this vaccination strategy synergized PD-L1 blockade mediated tumor suppression. Notably, prime-boost vaccination extended the duration of PD-L1 blockade induced antitumor effects by preventing the re-exhaustion of tumor-specific CD8(+) T cells. CONCLUSION: CD4(+) T cell epitope-based heterologous prime-boost vaccination elicited potent both tumor-specific T(H)1 and CTL response, leading to the efficient tumor control. This strategy can also potentiate PD-1/PD-L1 immune checkpoint blockade (ICB) against cancer. BMJ Publishing Group 2022-05-16 /pmc/articles/PMC9114852/ /pubmed/35580929 http://dx.doi.org/10.1136/jitc-2021-004022 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Clinical/Translational Cancer Immunotherapy
Xiao, Minglu
Xie, Luoyingzi
Cao, Guoshuai
Lei, Shun
Wang, Pengcheng
Wei, Zhengping
Luo, Yuan
Fang, Jingyi
Yang, Xingxing
Huang, Qizhao
Xu, Lifan
Guo, Junyi
Wen, Shuqiong
Wang, Zhiming
Wu, Qing
Tang, Jianfang
Wang, Lisha
Chen, Xiangyu
Chen, Cheng
Zhang, Yanyan
Yao, Wei
Ye, Jianqiang
He, Ran
Huang, Jun
Ye, Lilin
CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
title CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
title_full CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
title_fullStr CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
title_full_unstemmed CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
title_short CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
title_sort cd4(+) t-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and pd-1/pd-l1 immunotherapy
topic Clinical/Translational Cancer Immunotherapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114852/
https://www.ncbi.nlm.nih.gov/pubmed/35580929
http://dx.doi.org/10.1136/jitc-2021-004022
work_keys_str_mv AT xiaominglu cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT xieluoyingzi cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT caoguoshuai cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT leishun cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT wangpengcheng cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT weizhengping cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT luoyuan cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT fangjingyi cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT yangxingxing cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT huangqizhao cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT xulifan cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT guojunyi cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT wenshuqiong cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT wangzhiming cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT wuqing cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT tangjianfang cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT wanglisha cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT chenxiangyu cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT chencheng cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT zhangyanyan cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT yaowei cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT yejianqiang cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT heran cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT huangjun cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy
AT yelilin cd4tcellepitopebasedheterologousprimeboostvaccinationpotentiatesantitumorimmunityandpd1pdl1immunotherapy